Research Shows New Treatment Could Delay Cancer Progression in Patients With High-Risk Smoldering Multiple Myeloma

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression.

Results from a phase 3 clinical trial, published in the New England Journal of Medicine and presented at this week's American Society of Hematology meeting, demonstrated that daratumumab, a monoclonal antibody that targets CD38, a protein found on the surface of myeloma cells, significantly reduces the risk of progression to active multiple myeloma and improves overall survival compared to active monitoring.

Smoldering multiple myeloma is a condition in which abnormal plasma cells accumulate in the bone marrow but do not display symptoms of active multiple myeloma. High-risk SMM, however, carries a significant risk of progressing to active disease. Until now, there has been no approved treatment for this high-risk group.

The multicenter, international AQUILA study randomly assigned 390 patients with high-risk SMM to receive either daratumumab or active monitoring. After a median follow-up of 65.2 months, the study demonstrated a 51% reduction in the risk of disease progression or death for those receiving daratumumab. At five years, 63.1% of patients in the daratumumab group remained progression-free, compared to 40.8% in the active monitoring group. Survival at five years was also significantly higher in the daratumumab group (93% vs. 86.9%).

"These results are a major advancement in the treatment of high-risk smoldering multiple myeloma," says S. Vincent Rajkumar, M.D., hematologist, Mayo Clinic Comprehensive Cancer Center and lead investigator of the trial. "For the first time, we have a treatment option that can significantly delay or prevent the progression to active disease, improving the lives of patients and offering them a chance at a longer, healthier future."

While hypertension was the most common side effect, occurring in a small percentage of patients in both groups, no new safety concerns were identified with daratumumab.

"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of Medicine in honor of Edward C. Rosenow III, M.D.

Patients should discuss this new treatment option with their healthcare team to determine if it is appropriate for their individual circumstances.

Learn more about the evolution and treatment of multiple myeloma on the Mayo Clinic Comprehensive Cancer Center blog.

For a detailed list of the authors and disclosures, see the full paper here.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

About Mayo Clinic Comprehensive Cancer Center
Designated as a comprehensive cancer center by the National Cancer Institute, Mayo Clinic Comprehensive Cancer Center is defining the cancer center of the future, focused on delivering the world's most exceptional patient-centered cancer care for everyone. At Mayo Clinic Comprehensive Cancer Center, a culture of innovation and collaboration is driving research breakthroughs in cancer detection, prevention and treatment to change lives.